- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT05028972
Discapacidad auditiva, estrategias y resultados en los departamentos de emergencia de VA (HearVA-ED)
Implementación de HearVA (I-HearVA)
HearVA involves six VA facility emergency departments (ED) over a 3-year intervention period. The first part of this study will test whether providing personal amplifiers to Veteran ED patients who self-report hearing difficulty is acceptable to these patients, can improve their hearing, enhance understanding of discharge instructions, and can reduce the risk of coming back to the ED in a short period of time (3 days and 30 days). The second part of the study will then identify whether ED staff can implement this program and achieve similar results. The second part will give ED staff increasing levels of responsibility for screening Veterans for hearing difficulty and providing personal amplifiers when such difficulty is detected.
Descripción general del estudio
Estado
Intervención / Tratamiento
Descripción detallada
HearVA is a randomized controlled trial to explore the utility and outcomes of providing point-of-care access to hearing-impaired Veterans, comparing an offer of personal amplifiers versus control in an environment where the clinical stakes are high. It addresses a knowledge gap about the utility of providing such hearing assistance during clinical encounters. The study measures whether providing personal amplifiers is acceptable to older patients, can improve hearing, enhance understanding of discharge instructions, and improve care transitions at discharge. If such a strategy is beneficial, this simple low-tech approach has great potential for implementation and wide dissemination. HearVA-ED has two phases - the first, which has been completed, established the feasibility and acceptability of research and procedures in the ED environment through a pilot efficacy study and the second phase will be to complete a larger more definitive efficacy study and a detailed implementation study resulting in a strategic approach that can be widely disseminated across all VA emergency departments throughout the United States. This second phase will use a mixed-methods, hybrid effectiveness-implementation design to implement and evaluate the hearing assistance intervention in six VA Emergency Department Sites (in different facilities across the country). Implementation will occur in four stages with variation in the starting sequence at each site: The first group of two VA emergency departments will initiate implementation with an efficacy trial; second group of two sites will initiate implementation with delivery and support of personal amplifiers after screening and randomization by a research assistant (Stage 1); the third group of two sites will initiate implementation with the entire implementation (Stage 2) and the presence of a research assistant to conduct discharge interviews; and all sites will progress from this sequence to Stage 3 - Sustainability - which is the full implementation without research assistant presence.
Tipo de estudio
Inscripción (Estimado)
Fase
- No aplica
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Joshua Chodosh, MD MSHS
- Número de teléfono: 48491 (310) 478-3711
- Correo electrónico: Joshua.Chodosh@va.gov
Copia de seguridad de contactos de estudio
- Nombre: Lin T Tun
- Número de teléfono: (646) 501-4132
- Correo electrónico: lin.tun@va.gov
Ubicaciones de estudio
-
-
Colorado
-
Aurora, Colorado, Estados Unidos, 80045-7211
- Reclutamiento
- Rocky Mountain Regional VA Medical Center, Aurora, CO
-
Contacto:
- Lauren Abbate, MD
- Número de teléfono: 3177 303-399-8020
- Correo electrónico: lauren.abbate@va.gov
-
-
New York
-
New York, New York, Estados Unidos, 10010-5011
- Reclutamiento
- VA NY Harbor Healthcare System, New York, NY
-
Investigador principal:
- Joshua Chodosh, MD MSHS
-
Contacto:
- Olga Dotsenko
- Número de teléfono: 3323 (212) 686-7500
- Correo electrónico: olga.dotsenko@va.gov
-
Contacto:
- Andrea M Aquines
- Número de teléfono: (212) 686-7500
- Correo electrónico: andrea.aquines@va.gov
-
Syracuse, New York, Estados Unidos, 13210-2716
- Activo, no reclutando
- Syracuse VA Medical Center, Syracuse, NY
-
The Bronx, New York, Estados Unidos, 10468
- Reclutamiento
- James J. Peters VA Medical Center, Bronx, NY
-
Contacto:
- Ula Hwang, MD
- Número de teléfono: 3816 718-584-9000
- Correo electrónico: ula.hwang@va.gov
-
-
North Carolina
-
Durham, North Carolina, Estados Unidos, 27705-3875
- Reclutamiento
- Durham VA Medical Center, Durham, NC
-
Contacto:
- Luna Ragsdale, MD
- Correo electrónico: luna.ragsdale@va.gov
-
-
Texas
-
Dallas, Texas, Estados Unidos, 75216-7167
- Reclutamiento
- VA North Texas Health Care System Dallas VA Medical Center, Dallas, TX
-
Contacto:
- Rohit Manaktala, MD
- Correo electrónico: Rohit.Manaktala@va.gov
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- English speaking
- Emergency severity index criterion of 3 (medium), 4, or 5 (low acuity)
- Hearing Handicap Inventory-Screen greater than or equal to 10 or positive answer to a single-item screening question
- Capacity to consent to participate in research
Exclusion Criteria:
- Inability to consent to participate in research
- Emergency severity index criterion of 1-2 (high acuity)
- Hearing Handicap Inventory-Screen less than 10 and negative answer to single item screening question
- Inability to speak English
- Using cochlear implants
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Intervention: Personal Amplifier
Consenting participants will be randomly assigned to the intervention group while receiving care in the emergency department |
The intervention group will receive personal amplifiers (PockeTalkers) while they receive care in the ED
Otros nombres:
|
|
Otro: Control: No Personal Amplifier
Consenting participants will be randomly assigned to the control group while receiving care in the emergency department |
The control group will not receive personal amplifiers while they receive care in the ED |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Emergency department (ED) 3-day Readmissions
Periodo de tiempo: 3-5 days after initial ED stay
|
The Investigators will determine whether patients have had an ED revisit within three days through CPRS review as well as a brief follow-up phone call 3-5 days after ED discharge |
3-5 days after initial ED stay
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Emergency department (ED) 30-day Readmissions
Periodo de tiempo: 30-35 days after initial ED stay
|
The Investigators will determine whether patients have had an ED revisit within 30 days through CPRS review as well as a brief follow-up phone call 30-35 days after ED discharge |
30-35 days after initial ED stay
|
|
Patient-Rated Quality of Hearing, Understanding, and Communication With Providers During Emergency department (ED) Stay
Periodo de tiempo: Duration of ED stay, average of 1 day
|
Participants will self-rate their quality of hearing, understanding, and communication using a six item questionnaire. Scored on a 10-point Likert scale (1 = do not agree at all; 10 = completely agree) the questions will be: When I talked to the doctors and nurses today ... (1) their voices were very clear; (2) I was able to hear the sounds that I wanted to hear; (3) noises did not cause a problem for my hearing; and (4) listening did not make me tired. Two additional statements will explicitly capture understanding: (5) I was able to understand what they said; and (6) I was able to understand without making an effort. Higher scores will indicate better communication and understanding with providers. |
Duration of ED stay, average of 1 day
|
|
Patient-Rated Quality of Post-Discharge Care
Periodo de tiempo: At time of discharge from ED, average 1 day
|
Patient-rated quality of post-discharge care using a three-item subset of the Care Transition Measure (CTM). The questions are scored on a 1-4 scale (1= strongly disagree; 4 = strongly agree): (1) The ED staff considered my preferences and those of my family or caregiver in deciding what my healthcare needs were for discharge; (2) Leaving the ED, I have a good understanding of the things I am responsible for in managing my health; (3) Leaving the ED, I clearly understand the purpose for each of my medications. Higher scores will indicate better discharge preparation. |
At time of discharge from ED, average 1 day
|
|
Self-Reported Understanding of Discharge Instructions
Periodo de tiempo: 3-5 days after initial ED stay
|
Investigators will gauge self-reported understanding of discharge instructions using semi-structured interview data compared to documented discharge data. |
3-5 days after initial ED stay
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Joshua Chodosh, MD MSHS, VA NY Harbor Healthcare System, New York, NY
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- IIR 17-068-1
- HX002421 (Otro número de subvención/financiamiento: VA HSR&D)
- 5I01HX002421-08 (Subvención/contrato del NIH de EE. UU.)
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
producto fabricado y exportado desde los EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .